Cargando…

Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease

Multicentric Castleman’s disease (MCD) is a rare, widespread lymphoproliferative disorder and a life-threatening disease involving hyperactivity of the immune system, excessive proinflammatory cytokine release, immune cell proliferation, and organ system dysfunction. Interleukin-6 (IL-6) is a cytoki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sitenga, Jenna, Aird, Gregory, Ahmed, Aabra, Silberstein, Peter T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769562/ https://www.ncbi.nlm.nih.gov/pubmed/29391839 http://dx.doi.org/10.2147/PROM.S140011

Ejemplares similares

Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease
por: Chrysochoou, Stamatios, et al.
Publicado: (2022)

Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab
por: van Rhee, Frits, et al.
Publicado: (2015)

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
por: van Rhee, Frits, et al.
Publicado: (2020)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

Emerging treatments in Castleman disease – a critical appraisal of siltuximab
por: Koff, Jean L, et al.
Publicado: (2016)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
por: Lang, Evan, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
por: Shupo, Francis, et al.
Publicado: (2023)

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE
por: van Rhee, F., et al.
Publicado: (2022)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2015)

POEMS Syndrome: Presented as Idiopathic Multicentric Castleman Disease of Plasma Cell Variant for Eight Years and Dramatic Treatment with Siltuximab Followed by Autologous Peripheral Blood Stem Cell Transplantation
por: Lee, Yong-Moon, et al.
Publicado: (2022)

Multicentric Castleman disease and the evolution of the concept
por: Zhou, Ting, et al.
Publicado: (2021)

Updates on the diagnosis and management of multicentric Castleman disease
por: Wu, Ya-Ju, et al.
Publicado: (2020)

Candidate biomarkers for idiopathic multicentric Castleman disease
por: Sumiyoshi, Remi, et al.
Publicado: (2022)

van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.
Publicado: (2023)

Clinical Features and Surgical Treatment of Schwannoma Affecting the Base of the Tongue: A Systematic Review
por: Sitenga, Jenna Lamendola, et al.
Publicado: (2017)

HIV-associated multicentric Castleman's disease
por: Naime, Fauzia de Fátima, et al.
Publicado: (2012)

Siltuximab (CNTO 328): a promising option for human malignancies
por: Chen, Runzhe, et al.
Publicado: (2015)

A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease
por: Butzmann, Alexandra, et al.
Publicado: (2021)

Possible Association of Multicentric Castleman's Disease with Autoimmune Lymphoproliferative Syndrome
por: Minemura, Hiroyuki, et al.
Publicado: (2018)

Multicentric Castleman's disease: Report of three cases
por: Guazzaroni, M., et al.
Publicado: (2018)

Multicentric Castleman's disease: a case report
por: Menezes, Brian F, et al.
Publicado: (2007)

Multicentric Castleman disease with TAFRO syndrome and Sjögren's
por: Li, Zi Ying, et al.
Publicado: (2019)

Multicentric Castleman disease with infiltration of eosinophils to the lung
por: Nakai, Shogo, et al.
Publicado: (2021)

Alveolar Hemorrhage in Idiopathic Multicentric Castleman’s Disease
por: Huang, Lingtong, et al.
Publicado: (2023)

Factors Affecting Adjuvant Therapy in Stage III Pancreatic Cancer—Analysis of the National Cancer Database
por: Krishnan, Mridula, et al.
Publicado: (2017)

A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab
por: Villaescusa, Lucinda, et al.
Publicado: (2022)

Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease
por: Li, Feng, et al.
Publicado: (2018)

Irreversible Kidney Damage due to Multicentric Castleman's Disease
por: Kahn, Fredrik, et al.
Publicado: (2008)

Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura
por: Sood, Ruchi, et al.
Publicado: (2013)

Co-Existence of Multicentric Castleman's Disease and Kaposi's Sarcoma
por: Yaghoobi, Reza, et al.
Publicado: (2015)

Idiopathic Multicentric Hyaline Vascular-Type Castleman Disease
por: Moutinho, Adelaide, et al.
Publicado: (2021)

Different Types of Skin Lesions in Multicentric Castleman Disease
por: Nakamura, Yoshihiro, et al.
Publicado: (2022)

Multicentric Castleman Disease of the Supraglottis: A Surgeons’ Dilemma
por: Jumaat, Anna Fariza, et al.
Publicado: (2023)

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
por: Pierson, Sheila K., et al.
Publicado: (2023)

Steroids/tacrolimus: HHV-8 related multicentric Castleman disease : case report
Publicado: (2021)

Experience with the use of siltuximab in patients with SARS-CoV-2 infection
por: Meira, Fernanda, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis
por: González García, Andrés, et al.
Publicado: (2022)

Sustained remission of Multicentric Castleman Disease in children treated with tocilizumab
por: Galeotti, C, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4h2dks6buq74ej2qc18mv4hh5d